daratumumab,talquetamab,teclistamab,pomalidomide
janssen,genmab
['trimm-2', 'congrat']
congratulations on the great presentation here at #asco23 on updated trimm-2 study. more progress being made in myeloma. 
VP of Oncology Global Medical Affairs at Janssen, J&J

Scientist focused on bringing new treatment options for pts with cancer. Tweets/views shared are my own